3D‐Quantitative Structure–Activity Relationship Studies on Benzothiadiazepine Hydroxamates as Inhibitors of Tumor Necrosis Factor‐α Converting Enzyme

A set of 29 benzothiadiazepine hydroxamates having selective tumor necrosis factor‐α converting enzyme inhibitory activity were used to compare the quality and predictive power of 3D‐quantitative structure–activity relationship, comparative molecular field analysis, and comparative molecular similarity indices models for the atom‐based, centroid/atom‐based, data‐based, and docked conformer‐based alignment. Removal of two outliers from the initial training set of molecules improved the predictivity of models. Among the 3D‐quantitative structure–activity relationship models developed using the above four alignments, the database alignment provided the optimal predictive comparative molecular field analysis model for the training set with cross‐validated r2 (q2) = 0.510, non‐cross‐validated r2 = 0.972, standard error of estimates (s) = 0.098, and F = 215.44 and the optimal comparative molecular similarity indices model with cross‐validated r2 (q2) = 0.556, non‐cross‐validated r2 = 0.946, standard error of estimates (s) = 0.163, and F = 99.785. These models also showed the best test set prediction for six compounds with predictive r2 values of 0.460 and 0.535, respectively. The contour maps obtained from 3D‐quantitative structure–activity relationship studies were appraised for activity trends for the molecules analyzed. The comparative molecular similarity indices models exhibited good external predictivity as compared with that of comparative molecular field analysis models. The data generated from the present study helped us to further design and report some novel and potent tumor necrosis factor‐α converting enzyme inhibitors.

[1]  G R Marshall,et al.  3D-QSAR: a current perspective. , 1995, Trends in pharmacological sciences.

[2]  J. Buolamwini,et al.  CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site. , 2002, Journal of medicinal chemistry.

[3]  P. Reinemer,et al.  The metzincins — Topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a super family of zinc‐peptidases , 1995, Protein science : a publication of the Protein Society.

[4]  R. Giridhar,et al.  3D-QSAR CoMFA/CoMSIA studies on 5-aryl-2,2-dialkyl-4-phenyl-3(2H)-furanone derivatives, as selective COX-2 inhibitors. , 2006, Acta pharmaceutica.

[5]  Sujit Roy,et al.  3-D QSAR studies on new dibenzyltin(IV) anticancer agents by comparative molecular field analysis (CoMFA). , 2002, Bioorganic & medicinal chemistry letters.

[6]  Johann Gasteiger,et al.  Multivariate structure‐activity relationships between data from a battery of biological tests and an ensemble of structure descriptors: The PLS method , 1984 .

[7]  S. Wold,et al.  The Collinearity Problem in Linear Regression. The Partial Least Squares (PLS) Approach to Generalized Inverses , 1984 .

[8]  Kurt Varmuza,et al.  Multivariate Data Analysis in Chemistry , 2008 .

[9]  S. Mandlekar,et al.  Design, Synthesis, and Evaluation of Benzothiadiazepine Hydroxamates as Selective Tumor Necrosis Factor-α Converting Enzyme Inhibitors , 2003 .

[10]  D. E. Patterson,et al.  Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies , 1988 .

[11]  Xiaomin Luo,et al.  Molecular docking and 3D-QSAR studies on gag peptide analogue inhibitors interacting with human cyclophilin A. , 2002, Journal of Medicinal Chemistry.

[12]  D. Ferguson,et al.  QSAR and CoMFA: a perspective on the practical application to drug discovery. , 2000, Drug design and discovery.

[13]  R. Giridhar,et al.  Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA. , 2006, European journal of medicinal chemistry.

[14]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[15]  R. Black Tumor necrosis factor-alpha converting enzyme. , 2002, The international journal of biochemistry & cell biology.

[16]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[17]  A Tropsha,et al.  Cross-validated R2-guided region selection for comparative molecular field analysis: a simple method to achieve consistent results. , 1995, Journal of medicinal chemistry.

[18]  N. Hooper,et al.  Families of zinc metalloproteases , 1994, FEBS letters.

[19]  H. Kubinyi Comparative Molecular Field Analysis (CoMFA) , 2002 .

[20]  B. Jaffee,et al.  Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release. , 2001, Journal of Medicinal Chemistry.

[21]  Eamonn F. Healy,et al.  Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model , 1985 .

[22]  Bing Xiong,et al.  Inhibitory mode of 1,5-diarylpyrazole derivatives against cyclooxygenase-2 and cyclooxygenase-1: molecular docking and 3D QSAR analyses. , 2002, Journal of medicinal chemistry.

[23]  Wolfgang Sippl,et al.  Receptor-based 3D QSAR analysis of estrogen receptor ligands – merging the accuracy of receptor-based alignments with the computational efficiency of ligand-based methods , 2000, J. Comput. Aided Mol. Des..

[24]  R. Giridhar,et al.  3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach. , 2006, Bioorganic & medicinal chemistry letters.

[25]  W. Welsh,et al.  Three-dimensional quantitative structure-activity relationship (3D-QSAR) models for a novel class of piperazine-based stromelysin-1 (MMP-3) inhibitors: applying a "divide and conquer" strategy. , 2001, Journal of medicinal chemistry.

[26]  W A Buurman,et al.  Tumor necrosis factor: function, release and clearance. , 1996, Critical reviews in immunology.

[27]  R. Giridhar,et al.  Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models. , 2008, European journal of medicinal chemistry.

[28]  E. Eisenstein,et al.  Ligand binding-promoted conformational changes in yeast ornithine transcarbamoylase. , 1986, The Journal of biological chemistry.

[29]  J. Sufrin,et al.  Steric mapping of the L-methionine binding site of ATP:L-methionine S-adenosyltransferase. , 1981, Molecular pharmacology.

[30]  Matthew Clark,et al.  Comparative molecular field analysis (CoMFA). 2. Toward its use with 3D-structural databases , 1990 .

[31]  H. Berendsen,et al.  Computer simulation of the dynamics of hydrated protein crystals and its comparison with x-ray data. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[32]  James J. P. Stewart,et al.  MOPAC: A semiempirical molecular orbital program , 1990, J. Comput. Aided Mol. Des..